Dosing Problems Cause Side Effects with GLP-1s

The side effects that push people off GLP-1s are often not the drug's fault. They are a dosing problem. Standard titration starts at a fixed dose and roughly doubles every four weeks. That schedule was built for a population average. It was not built for you, or for someone who is already metabolically unwell, or for someone whose liver and kidneys process the drug differently than the trial median. When the dose is too high you see it before the patient says anything. Mood goes flat, and food loses all appeal. Resting heart rate creeps up, HRV drops, sleep quality falls. If you are not measuring those things you just hear "I felt terrible and I stopped." And then they stop. And the STEP 1 extension data showed what happens after stopping: about two thirds of the weight lost came back within a year, and the cardiometabolic improvements drifted with it. So the cost of a dropout is not just a bad experience. It's a lost clinical outcome. The low-dose approach some GLP-1 clinicians use, starting at a fifth to a tenth of the standard starting dose, isn't microdosing in the pharmacology sense. But it makes sense to find the dose where appetite is controlled, not suppressed, and stay there. Past that threshold people under-eat, lose muscle with the fat, and feel bad enough to quit. You cannot find that threshold without measuring. Fasting insulin, body composition by DEXA, a CGM, a wearable tracking HRV and sleep. Check labs during treatment, not just before. Labs can move before weight does, and a wearable tells you something is wrong between blood draws. Prescribing before measuring and not measuring again while the patient is on the drug is a mistake. The dose that was right at week four may not be right at week twelve. Personalised dosing is not a premium add-on. It is the difference between a drug working and a patient quitting something that was actually helping them.